Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INKT
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
INKT
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

INKT Similar Chart Price Prediction

The price of INKT is predicted to go up 4.73%, based on the high correlation periods with BK. The similarity of these two price pattern on the periods is 93.99%.

stocks logo

INKT

stocks logo

BK

Up: 4.73%Similarity: 93.99%

INKT Revenue Forecast

INKT EPS Forecast

INKT FAQs

What is bull’s view on INKT?

MiNK Therapeutics (INKT) is currently trading at $1.69, with a bullish outlook driven by its promising pipeline. The ongoing Phase 2 trial of AgenT-797 for gastric cancer and the preclinical progress of MiNK-215 highlight strong growth potential. Analysts have set a price target of $9, reflecting significant upside based on clinical advancements and strategic collaborations.

What is bear's view on INKT?

INKT stock currently trades at $1.69, reflecting a bearish sentiment due to its limited financial runway and reduced price targets by analysts. Despite promising clinical developments like AGENT-797 in Phase 2 trials, the stock faces challenges from high cash burn and reliance on external funding. The lowered price target to $4 by Baird indicates cautious optimism but highlights significant risks.

What is INKT eps forecast for next quarter？

The market consensus for INKT's eps in the upcoming quarter is projected to be approximately $0.60 USD.

INKT VS S&P500

Ask Intellectia about INKT

INKT Analyst's Forecast

Jack Allen

Baird

Buy

Price Target

$8 → $4

Upside

+430.5%

Baird analyst Jack Allen lowered the firm's price target on MiNK Therapeutics to $4 from $8 and keeps an Outperform rating on the shares. The firm said the company announced 3Q24 financials and provided pipeline updates, which were generally in line with expectations.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free